IF YOU HAVE BEEN DIAGNOSED WITH BLADDER CANCER AFTER TAKING ACTOS, SPEAK WITH OUR ATTORNEYS TODAY
The U.S. Food and Drug Administration (FDA) warns that use of the diabetes medication Actos® (pioglitazone) for more than one year has been associated with a 40 percent increase in risk for bladder cancer. The FDA urges patients that have taken Actos to contact a medical professional immediately if they experience any of the following symptoms:
- Blood or red color in urine
- Urgent need to urinate or pain while urinating
- Pain in back or lower abdomen
Information about the risk of bladder cancer associated with Actos has been added to the Warnings and Precautions section of the label for pioglitazone-containing medicines as well as the patient medication guide.
Different Products, Same Risk
The active ingredient in Actos (pioglitazone) is also sold in combination with metformin (Actoplus Met®, Actoplus Met XR®) and glimepiride (Duetact®). From January 2010 through October 2010, approximately 2.3 million patients filled a prescription for a pioglitazone-containing product from outpatient retail pharmacies.
Get the Help You Deserve
When you’ve been seriously injured, you have questions—turn to Schmidt Kramer and speak with a lawyer today. Our Pennsylvania antidepressant birth defects attorneys will walk you through the legal process and get you back on your feet. Call (888) 476-0807 or fill out a free online consultation form—it's yet another way to Talk to a Lawyer.
Never stop taking any medication without first consulting your doctor. Actos®, Actoplus Met®, Actoplus Met XR®, and Duetact® are registered trademarks of Takeda Pharmaceutical Company Limited and are used here only for the purpose of identifying the products in question. This law firm is not associated with, sponsored by, or affiliated with the U.S. Food and Drug Administration or Takeda Pharmaceutical Company Limited.